Amine Mazine

Amine Mazine

Auto-generated profile, based on publicly available information

Amine Mazine

Department of Cardiac Surgery, Royal Children's Hospital, Melbourne, VIC, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Cell Stem Cell
Verified
Journal Article
Closed access
AMAlexander A. Mikryukov
Alexander A. Mikryukov
AMAmine Mazine
Amine Mazine
BWBei Wei
Bei Wei
DYDonghe Yang
Donghe Yang
YMYifei Miao
Yifei Miao
GKGordon M. Keller
Gordon M. Keller

1 September 2018 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
DTDerrick Y. Tam
Derrick Y. Tam
BYBobby Yanagawa
Bobby Yanagawa
SVSubodh Verma
Subodh Verma
MRMarc Ruel
Marc Ruel
SFStephen E. Fremes
Stephen E. Fremes
JFJan O. Friedrich
Jan O. Friedrich

1 March 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
BYBobby Yanagawa
Bobby Yanagawa
RRRodolfo V. Rocha
Rodolfo V. Rocha
AMAmine Mazine
Amine Mazine
SVSubodh Verma
Subodh Verma
CMC. David Mazer
C. David Mazer
JFJohn Freedman
John Freedman
We report our 10-year experience of a multicenter hemoglobin optimization program with the aim to reduce red blood cell transfusion in patients undergoing coronary artery bypass grafting (CABG). From 2006 to 2016, patients undergoing CABG at 10 centers in Ontario were referred to the Ontario Transfusion Coordinators (ONTraC) program. Of these, we present data on the first 60 consecutive patients per center, per year (n = 6,145). Overall, 45.7% patients were assessed <14 days preoperatively, 16.4% were assessed ≥14 days preoperatively, and 37.9% were not assessed by ONTraC preoperatively. Transfusion rates fell from 40.1% in 2006 to 26.2% in 2016 (p < 0.01). Patients undergoing assessment were more likely to be older (p < 0.01), female (p < 0.01), and anemic (p < 0.01) versus nonassessed patients. Those patients assessed were more likely to be treated with iron (p < 0.01) and erythropoietin (p < 0.01) preoperatively versus nonassessed patients. Transfusion rates were 26%, 28%, and 28% for patients undergoing assessment ≥14 days prior to operation, <14 days prior to operation, or not at all. After baseline covariate adjustment, patients assessed ≥14 days preoperatively had shorter length of stay (effect -0.83, 95% confidence interval [CI] -1.41 to -0.25; p < 0.01) and a trend towards lower risk of red blood cell transfusion (odds ratio [OR] 0.83, 95% CI 0.68 to 1.00; p = 0.06). Blood transfusion was independently associated with an increased risk of death (OR 1.49, 95% CI 1.37 to 1.60; p < 0.01), infection (OR 1.24, 95% CI 1.18 to 1.30; p < 0.01), and longer hospital length of stay (effect 1.49, 95% CI 1.35 to 1.62; p < 0.01). The results of this study suggest that preoperative hemoglobin optimization may be effective in reducing red blood cell transfusion after CABG, particularly for patients assessed ≥14 days preoperatively.

1 December 2020 in Journal of Surgical Research
Verified
Journal Article
Closed access
KZKevin J. Zuo
Kevin J. Zuo
YMYing Meng
Ying Meng
LGLauren Gordon
Lauren Gordon
TSTomas J. Saun
Tomas J. Saun
AMAmine Mazine
Amine Mazine
Michael FehlingsMichael Fehlings
Michael Fehlings

1 August 2016 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
AGAly Ghoneim
Aly Ghoneim
IBIsmail Bouhout
Ismail Bouhout
AMAmine Mazine
Amine Mazine
WFWilliam Fortin
William Fortin
IEIsmail El-Hamamsy
Ismail El-Hamamsy
DBDenis Bouchard
Denis Bouchard

21 September 2025 in bioRxiv
Verified
Preprint
Open access
AMAmine Mazine
Amine Mazine
AMAlexander A. Mikryukov
Alexander A. Mikryukov
IFIan Fernandes
Ian Fernandes
CLClifford Z. Liu
Clifford Z. Liu
SJSoheil Jahangiri
Soheil Jahangiri
GKGordon M. Keller
Gordon M. Keller
Heart valves are living structures whose sophisticated functions are mediated by a specialized population of mesenchymal cells known as valvular interstitial cells (VICs). Given their central role in valve homeostasis, VICs represent a promising cell population for studying heart valve diseases and developing novel therapies to treat them. Here, we describe a strategy for generating VICs from human pluripotent stem cells (hPSCs) by stage-specific manipulation of developmental signalling pathways. Our results demonstrate that hPSC-derived VICs show a high transcriptional similarity to primary human fetal VICs and can secrete key proteins of the valve extracellular matrix. We further investigate the heterogeneity of hPSC-derived VICs and identify two major subpopulations with distinct molecular and functional properties, mirroring the cellular diversity observed in vivo . Finally, we utilize an in vitro model of Noonan syndrome to demonstrate that hPSC-derived VICs can accurately recapitulate key aspects of valve disease. Collectively, these findings provide a reproducible method for the scaled generation of bona fide hPSC-derived VICs and establish their utility in disease modelling and tissue engineering applications. Clinical Perspective: What is new?: - We established a robust platform to generate bona fide valvular interstitial cells (VICs) from human pluripotent stem cells (hPSCs), recapitulating native VIC identity and function. - We delineated signaling pathways that promote the development of two distinct VIC subsets and identified a surface marker to distinguish between them. What are the clinical implications?: - A renewable, human-specific source of VICs enables precise mechanistic studies of valve development and disease that are not possible with limited surgical specimens or animal models. - This platform creates opportunities for therapeutic applications, including drug discovery and tissue engineering approaches for valve repair.